Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares shot up 3.1% during trading on Monday . The stock traded as high as $1.77 and last traded at $1.68. 449,700 shares traded hands during trading, an increase of 52% from the average session volume of 296,297 shares. The stock had previously closed at $1.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Tiziana Life Sciences Stock Up 3.1%

The stock’s fifty day moving average price is $1.61 and its 200-day moving average price is $1.80.

Institutional Trading of Tiziana Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the fourth quarter worth about $30,000. Cubist Systematic Strategies LLC acquired a new position in shares of Tiziana Life Sciences during the 1st quarter worth approximately $25,000. Jane Street Group LLC increased its position in shares of Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock worth $181,000 after purchasing an additional 151,858 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Tiziana Life Sciences during the 2nd quarter worth approximately $39,000. Finally, ARS Investment Partners LLC bought a new stake in shares of Tiziana Life Sciences during the 3rd quarter worth approximately $66,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.